Granted Patent
B2
US 12,419,957 · App. 18/821,068 · Granted Sep 23, 2025
Delivery and formulation of engineered nucleic acids
Assignee:
ModernaTX, Inc.
A61K47/18A61K31/7088A61K31/7115A61K38/193A61K38/4846A61K47/22A61K47/28C07K14/535C12N9/644C12N15/67C12N15/87A61K48/00C12N2310/335
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Provided are formulations, compositions and methods for delivering biological moieties such as modified nucleic acids into cells to modulate protein expression. Such compositions and methods include the delivery of biological moieties, and are useful for production of proteins.
Claims (20)
1. A messenger RNA (mRNA) comprising an open reading frame encoding a polypeptide, wherein the open reading frame comprises nucleosides consisting of N1-methyl-pseudouridine, adenosine, guanosine, and cytidine.
2. The mRNA of claim 1 , wherein the mRNA comprises, in the 5′ to 3′ direction,
(a) a 5′ cap structure
(b) a 5′-UTR;
(c) the open reading frame encoding the polypeptide;
(d) a 3′-UTR; and
(e) a polyA tail.
3. The mRNA of claim 2 , wherein the 5′ cap structure is a 5′ cap-1 having the following structure:
4. The mRNA of claim 2 , wherein the polyA tail is 100 nucleosides in length.
5. The mRNA of claim 2 , wherein the polyA tail is 100 nucleosides in length and the 5′ cap structure is a 5′ cap-1 having the following structure:
6. A pharmaceutical composition comprising a messenger RNA (mRNA) comprising an open reading frame encoding a polypeptide, wherein the open reading frame comprises nucleosides consisting of N1-methyl-pseudouridine, adenosine, guanosine, and cytidine.
7. The pharmaceutical composition of claim 6 , wherein the mRNA comprises, in the 5′ to 3′ direction,
(a) a 5′ cap structure
(b) a 5′-UTR;
(c) the open reading frame encoding the polypeptide;
(d) a 3′-UTR; and
(e) a polyA tail.
8. The pharmaceutical composition of claim 7 , wherein the 5′ cap structure is a 5′ cap-1 having the following structure:
9. The pharmaceutical composition of claim 7 , wherein the polyA tail is 100 nucleosides in length.
10. The pharmaceutical composition of claim 7 , wherein the polyA tail is 100 nucleosides in length and the 5′ cap structure is a 5′ cap-1 having the following structure:
Assignments (3)
SECURITY INTEREST
Recorded Nov 19, 2025
From: MODERNATX, INC.
To: ARES CAPITAL CORPORATION, AS AGENT
Reel/Frame 073634/0354 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 28, 2025
From: DE FOUGEROLLES, ANTONIN; ELBASHIR, SAYDA M.
To: MODERNA THERAPEUTICS, INC.
Reel/Frame 070362/0506 →
CHANGE OF NAME
Recorded Feb 28, 2025
From: MODERNA THERAPEUTICS, INC.
To: MODERNATX, INC.
Reel/Frame 070366/0659 →
Continuity (9)
Provisional Application
61470451
· Mar 31, 2011
References Cited (400)
US 5034506A
· Summerton et al.
· 1991
[cited by applicant]
US 5426180A
· Kool
· 1995
[cited by applicant]
US 5489677A
· Sanghvi et al.
· 1996
[cited by applicant]
US 5512439A
· Hornes et al.
· 1996
[cited by applicant]
US 5591722A
· Montgomery et al.
· 1997
[cited by applicant]
US 5637459A
· Burke et al.
· 1997
[cited by applicant]
US 5639873A
· Barascut et al.
· 1997
[cited by applicant]
US 5641400A
· Kaltenbach et al.
· 1997
[cited by applicant]
US 5789578A
· Burton et al.
· 1998
[cited by applicant]
US 5808039A
· Reddy et al.
· 1998
[cited by applicant]
US 5989911A
· Fournier et al.
· 1999
[cited by applicant]
US 6022715A
· Merenkova et al.
· 2000
[cited by applicant]
US 6022737A
· Niven et al.
· 2000
[cited by applicant]
US 6248268B1
· Cook
· 2001
[cited by applicant]
US 6303378B1
· Bridenbaugh et al.
· 2001
[cited by applicant]
US 6423492B1
· Harbron
· 2002
[cited by applicant]
US 6511832B1
· Guarino et al.
· 2003
[cited by applicant]
US 6521411B2
· Hecker et al.
· 2003
[cited by applicant]
US 7691569B2
· Wohlgemuth et al.
· 2010
[cited by applicant]
US 8075780B2
· Pearce
· 2011
[cited by applicant]
US 8093367B2
· Kore et al.
· 2012
[cited by applicant]
US 8664194B2
· de Fougerolles et al.
· 2014
[cited by applicant]
US 8680069B2
· de Fougerolles et al.
· 2014
[cited by applicant]
US 8691750B2
· Constien et al.
· 2014
[cited by applicant]
US 8710200B2
· Schrum et al.
· 2014
[cited by applicant]
US 8716465B2
· Rossi et al.
· 2014
[cited by applicant]
US 8802438B2
· Rossi et al.
· 2014
[cited by applicant]
US 8822663B2
· Schrum et al.
· 2014
[cited by applicant]
US 8883506B2
· Rossi et al.
· 2014
[cited by applicant]
US 8898864B1
· Porter
· 2014
[cited by applicant]
US 8969353B2
· Mahon et al.
· 2015
[cited by applicant]
US 8980864B2
· Hoge et al.
· 2015
[cited by applicant]
US 8999380B2
· Bancel et al.
· 2015
[cited by applicant]
US 9050297B2
· Chakraborty et al.
· 2015
[cited by applicant]
US 9061059B2
· Chakraborty et al.
· 2015
[cited by applicant]
US 9066867B2
· Panzner
· 2015
[cited by examiner]
US 9089604B2
· Chakraborty et al.
· 2015
[cited by applicant]
US 9095552B2
· Chakraborty et al.
· 2015
[cited by applicant]
US 9107886B2
· Chakraborty et al.
· 2015
[cited by applicant]
US 9114113B2
· Chakraborty et al.
· 2015
[cited by applicant]
US 9149506B2
· Chakraborty et al.
· 2015
[cited by applicant]
US 9428535B2
· de Fougerolles et al.
· 2016
[cited by applicant]
US 9533047B2
· de Fougerolles
· 2017
[cited by examiner]
US 9675668B2
· Bancel et al.
· 2017
[cited by applicant]
US 9803177B2
· Rossi et al.
· 2017
[cited by applicant]
US 9872900B2
· Ciaramella et al.
· 2018
[cited by applicant]
US 9950068B2
· De Fougerolles
· 2018
[cited by examiner]
US 20010025097A1
· Sheridan et al.
· 2001
[cited by applicant]
US 20020001812A1
· Smith et al.
· 2002
[cited by applicant]
US 20020016450A1
· Laugharn et al.
· 2002
[cited by applicant]
US 20020062017A1
· Hecker et al.
· 2002
[cited by applicant]
US 20020114784A1
· Li et al.
· 2002
[cited by applicant]
US 20020130430A1
· Castor
· 2002
[cited by applicant]
US 20020153312A1
· Gjerde et al.
· 2002
[cited by applicant]
US 20020164635A1
· Salerno
· 2002
[cited by applicant]
US 20030120035A1
· Gao et al.
· 2003
[cited by applicant]
US 20030170876A1
· Widner et al.
· 2003
[cited by applicant]
US 20030170891A1
· McSwiggen
· 2003
[cited by applicant]
US 20030180779A1
· Lofton-Day et al.
· 2003
[cited by applicant]
US 20040038278A1
· Tzertzinis et al.
· 2004
[cited by applicant]
US 20040142433A1
· Padgett et al.
· 2004
[cited by applicant]
US 20040220127A1
· Sternberg et al.
· 2004
[cited by applicant]
US 20040259097A1
· De Backer et al.
· 2004
[cited by applicant]
US 20050003496A1
· McGall et al.
· 2005
[cited by applicant]
US 20050130196A1
· Hofstadler et al.
· 2005
[cited by applicant]
US 20060058266A1
· Manoharan et al.
· 2006
[cited by applicant]
US 20060121441A1
· Spira
· 2006
[cited by applicant]
US 20060223081A1
· Jarrell et al.
· 2006
[cited by applicant]
US 20070020678A1
· Ault-Riche et al.
· 2007
[cited by applicant]
US 20070037148A1
· Fong et al.
· 2007
[cited by applicant]
US 20070037770A1
· Gryaznov et al.
· 2007
[cited by applicant]
US 20070244062A1
· Laux et al.
· 2007
[cited by applicant]
US 20070281336A1
· Jendrisak et al.
· 2007
[cited by applicant]
US 20080076910A1
· Takkellapati et al.
· 2008
[cited by applicant]
US 20080171711A1
· Hoerr et al.
· 2008
[cited by applicant]
US 20080274463A1
· Chen et al.
· 2008
[cited by applicant]
US 20080311140A1
· Lee et al.
· 2008
[cited by applicant]
US 20090215125A1
· Reed et al.
· 2009
[cited by applicant]
US 20090264511A1
· de Fougerolles et al.
· 2009
[cited by applicant]
US 20090286852A1
· Kariko et al.
· 2009
[cited by applicant]
US 20100015232A1
· Besenbacher et al.
· 2010
[cited by applicant]
US 20100047261A1
· Hoerr et al.
· 2010
[cited by applicant]
US 20100086922A1
· Bryant et al.
· 2010
[cited by applicant]
US 20100159456A1
· Albitar
· 2010
[cited by applicant]
US 20100178272A1
· Hartmann et al.
· 2010
[cited by applicant]
US 20100183639A1
· Uhlmann et al.
· 2010
[cited by applicant]
US 20100255574A1
· Rosen et al.
· 2010
[cited by applicant]
US 20100261228A1
· Gharib et al.
· 2010
[cited by applicant]
US 20100261231A1
· Kore et al.
· 2010
[cited by applicant]
US 20100317532A1
· Liu et al.
· 2010
[cited by applicant]
US 20110130440A1
· Manoharan et al.
· 2011
[cited by applicant]
US 20110143397A1
· Kariko et al.
· 2011
[cited by applicant]
US 20110218170A1
· Thottassery et al.
· 2011
[cited by applicant]
US 20110244026A1
· Guild et al.
· 2011
[cited by applicant]
US 20110281938A1
· Schaub et al.
· 2011
[cited by applicant]
US 20120046346A1
· Rossi et al.
· 2012
[cited by applicant]
US 20120100136A1
· Patel et al.
· 2012
[cited by applicant]
US 20120129261A1
· Eberwine et al.
· 2012
[cited by applicant]
US 20120251618A1
· Schrum et al.
· 2012
[cited by applicant]
US 20120309053A1
· Wellings
· 2012
[cited by applicant]
US 20130046083A1
· Brown et al.
· 2013
[cited by applicant]
US 20130046084A1
· Brown et al.
· 2013
[cited by applicant]
US 20130052721A1
· Hollander et al.
· 2013
[cited by applicant]
US 20130058894A1
· Maldonado et al.
· 2013
[cited by applicant]
US 20130115272A1
· de Fougerolles et al.
· 2013
[cited by applicant]
US 20130115274A1
· Knopov et al.
· 2013
[cited by applicant]
US 20130123481A1
· de Fougerolles et al.
· 2013
[cited by applicant]
US 20130156849A1
· de Fougerolles et al.
· 2013
[cited by applicant]
US 20130165504A1
· Bancel et al.
· 2013
[cited by applicant]
US 20130197068A1
· Kariko et al.
· 2013
[cited by applicant]
US 20130203115A1
· Schrum et al.
· 2013
[cited by applicant]
US 20130244282A1
· Schrum et al.
· 2013
[cited by applicant]
US 20130245103A1
· de Fougerolles et al.
· 2013
[cited by applicant]
US 20130245105A1
· de Fougerolles et al.
· 2013
[cited by applicant]
US 20130245106A1
· de Fougerolles et al.
· 2013
[cited by applicant]
US 20130251618A1
· Li et al.
· 2013
[cited by applicant]
US 20130259923A1
· Bancel et al.
· 2013
[cited by applicant]
US 20130259924A1
· Bancel et al.
· 2013
[cited by applicant]
US 20140010861A1
· Bancel et al.
· 2014
[cited by applicant]
US 20140105964A1
· Bancel et al.
· 2014
[cited by applicant]
US 20140105966A1
· Bancel et al.
· 2014
[cited by applicant]
US 20140147454A1
· Chakraborty et al.
· 2014
[cited by applicant]
US 20140200261A1
· Hoge et al.
· 2014
[cited by applicant]
US 20140206752A1
· Afeyan et al.
· 2014
[cited by applicant]
US 20140206852A1
· Hoge et al.
· 2014
[cited by applicant]
US 20140243399A1
· Schrum et al.
· 2014
[cited by applicant]
US 20140273230A1
· Chen et al.
· 2014
[cited by applicant]
US 20140275227A1
· Hoge et al.
· 2014
[cited by applicant]
US 20140343129A1
· de Fougerolles et al.
· 2014
[cited by applicant]
US 20140371302A1
· Afeyan et al.
· 2014
[cited by applicant]
US 20150005372A1
· Hoge et al.
· 2015
[cited by applicant]
US 20150017211A1
· de Fougerolles et al.
· 2015
[cited by applicant]
US 20150030576A1
· Bancel
· 2015
[cited by applicant]
US 20150050354A1
· Bouchon et al.
· 2015
[cited by applicant]
US 20150050738A1
· Ozsolak et al.
· 2015
[cited by applicant]
US 20150051268A1
· Bancel et al.
· 2015
[cited by applicant]
US 20150056253A1
· Bancel et al.
· 2015
[cited by applicant]
US 20150064235A1
· Bancel et al.
· 2015
[cited by applicant]
US 20150064236A1
· Bancel et al.
· 2015
[cited by applicant]
US 20150064725A1
· Schrum et al.
· 2015
[cited by applicant]
US 20150086614A1
· Bancel et al.
· 2015
[cited by applicant]
US 20150111248A1
· Bancel et al.
· 2015
[cited by applicant]
US 20150140120A1
· McCauley et al.
· 2015
[cited by applicant]
US 20150141269A1
· Soldatov et al.
· 2015
[cited by applicant]
US 20150141499A1
· Bancel et al.
· 2015
[cited by applicant]
US 20150166616A1
· Bancel et al.
· 2015
[cited by applicant]
US 20150167017A1
· Roy et al.
· 2015
[cited by applicant]
US 20150211039A1
· Wang et al.
· 2015
[cited by applicant]
US 20150307542A1
· Roy et al.
· 2015
[cited by applicant]
US 20160017313A1
· Spivak et al.
· 2016
[cited by applicant]
US 20160024140A1
· Issa et al.
· 2016
[cited by applicant]
US 20160024141A1
· Issa et al.
· 2016
[cited by applicant]
US 20160024492A1
· Issa et al.
· 2016
[cited by applicant]
US 20160024547A1
· Bancel et al.
· 2016
[cited by applicant]
US 20160032273A1
· Shahrokh et al.
· 2016
[cited by applicant]
US 20160038612A1
· Hoge et al.
· 2016
[cited by applicant]
US 20160177295A1
· Rudolph et al.
· 2016
[cited by applicant]
US 20160194368A1
· Hoge et al.
· 2016
[cited by applicant]
US 20160194625A1
· Hoge et al.
· 2016
[cited by applicant]
US 20160237108A1
· Fraley et al.
· 2016
[cited by applicant]
US 20160244742A1
· Linnarsson et al.
· 2016
[cited by applicant]
US 20160326575A1
· Von Der Mulbe et al.
· 2016
[cited by applicant]
US 20160354490A1
· Roy et al.
· 2016
[cited by applicant]
US 20160354491A1
· Roy et al.
· 2016
[cited by applicant]
US 20160354492A1
· Roy et al.
· 2016
[cited by applicant]
US 20160354493A1
· Roy et al.
· 2016
[cited by applicant]
US 20160367702A1
· Hoge et al.
· 2016
[cited by applicant]
US 20170088888A1
· El-Sagheer et al.
· 2017
[cited by applicant]
US 20170136131A1
· Roy et al.
· 2017
[cited by applicant]
US 20170136132A1
· Roy et al.
· 2017
[cited by applicant]
US 20170175129A1
· Roy et al.
· 2017
[cited by applicant]
CA 2028849A1
· 1991
[cited by applicant]
CA 2473135A1
· 2003
[cited by applicant]
EP 0366400A2
· 1990
[cited by applicant]
EP 1083232B1
· 2005
[cited by applicant]
EP 1611899A1
· 2006
[cited by applicant]
EP 1619254A1
· 2006
[cited by applicant]
EP 1383556B9
· 2008
[cited by applicant]
EP 1831160B1
· 2010
[cited by applicant]
EP 2092064B1
· 2010
[cited by applicant]
EP 2377938A1
· 2011
[cited by applicant]
EP 2484770A1
· 2012
[cited by applicant]
EP 2188379B1
· 2013
[cited by applicant]
EP 2548960A1
· 2013
[cited by applicant]
EP 3112467A1
· 2017
[cited by applicant]
EP 2510099B1
· 2017
[cited by applicant]
EP 3287525A1
· 2018
[cited by applicant]
EP 2578685B1
· 2019
[cited by applicant]
EP 2622064B1
· 2019
[cited by applicant]
EP 3492109A1
· 2019
[cited by applicant]
EP 3590949A1
· 2020
[cited by applicant]
EP 3682905B1
· 2021
[cited by applicant]
EP 2791160B1
· 2022
[cited by applicant]
EP 3611266B1
· 2022
[cited by applicant]
JP 2010530245A
· 2010
[cited by applicant]
JP 2010280714A
· 2010
[cited by applicant]
JP 2011130725A
· 2011
[cited by applicant]
JP 2014530601A
· 2014
[cited by applicant]
JP 2015513912A
· 2015
[cited by applicant]
JP 2018166528A
· 2018
[cited by applicant]
RU 2540017C2
· 2015
[cited by applicant]
WO WO9105058A1
· 1991
[cited by applicant]
WO WO9303052A1
· 1993
[cited by applicant]
WO WO9313121A1
· 1993
[cited by applicant]
WO WO9805673A1
· 1998
[cited by applicant]
WO WO9914346A2
· 1999
[cited by applicant]
WO WO0042175A1
· 2000
[cited by applicant]
WO WO200155306A2
· 2001
[cited by applicant]
WO WO0244399A2
· 2002
[cited by applicant]
WO WO03039523A2
· 2003
[cited by applicant]
WO WO03051881A1
· 2003
[cited by applicant]
WO WO2004020575A2
· 2004
[cited by applicant]
WO WO2004020576A2
· 2004
[cited by applicant]
WO WO2004064782A2
· 2004
[cited by applicant]
WO WO2004082703A1
· 2004
[cited by applicant]
WO WO2005039551A2
· 2005
[cited by applicant]
WO WO2006015445A1
· 2006
[cited by applicant]
WO WO2007024708A2
· 2007
[cited by applicant]
WO WO2007089607A2
· 2007
[cited by applicant]
WO WO2007120863A2
· 2007
[cited by applicant]
WO WO2008039669A1
· 2008
[cited by applicant]
WO WO2008045505A2
· 2008
[cited by applicant]
WO WO2008083949A2
· 2008
[cited by applicant]
WO WO2008120016A1
· 2008
[cited by applicant]
WO WO2008156829A2
· 2008
[cited by applicant]
WO WO2009051451A2
· 2009
[cited by applicant]
WO WO2009042971A2
· 2009
[cited by applicant]
WO WO2009127230A1
· 2009
[cited by applicant]
WO WO20090127060A1
· 2009
[cited by applicant]
WO WO2009147519A1
· 2009
[cited by applicant]
WO WO2009149253A2
· 2009
[cited by applicant]
WO WO2010014895A2
· 2010
[cited by applicant]
WO WO2010017510A1
· 2010
[cited by applicant]
WO WO2010042877A1
· 2010
[cited by applicant]
WO WO2010054401A1
· 2010
[cited by applicant]
WO WO2010109289A1
· 2010
[cited by applicant]
WO WO2010144740A1
· 2010
[cited by applicant]
WO WO2011005850A1
· 2011
[cited by applicant]
WO WO2011012316A2
· 2011
[cited by applicant]
WO WO2011068810A1
· 2011
[cited by applicant]
WO WO2011071931A2
· 2011
[cited by applicant]
WO WO2011127933A1
· 2011
[cited by applicant]
WO WO2011130624A2
· 2011
[cited by applicant]
WO WO2011133868A2
· 2011
[cited by applicant]
WO WO2011140627A1
· 2011
[cited by applicant]
WO WO2012019168A2
· 2012
[cited by applicant]
WO WO2012077080A1
· 2012
[cited by applicant]
WO WO2012135805A2
· 2012
[cited by applicant]
WO WO2012138530A1
· 2012
[cited by applicant]
WO WO2012158736A1
· 2012
[cited by applicant]
WO WO2012164565A1
· 2012
[cited by applicant]
WO WO2013036748A1
· 2013
[cited by applicant]
WO WO2013039857A1
· 2013
[cited by applicant]
WO WO2013039861A2
· 2013
[cited by applicant]
WO WO2013052523A1
· 2013
[cited by applicant]
WO WO2013064911A2
· 2013
[cited by applicant]
WO WO2013090186A1
· 2013
[cited by applicant]
WO WO2013090648A1
· 2013
[cited by applicant]
WO WO2013096709A2
· 2013
[cited by applicant]
WO WO2013090294A1
· 2013
[cited by applicant]
WO WO2013090897A1
· 2013
[cited by applicant]
WO WO2013101690A1
· 2013
[cited by applicant]
WO WO2013103659A1
· 2013
[cited by applicant]
WO WO2013113326A1
· 2013
[cited by applicant]
WO WO2013113501A1
· 2013
[cited by applicant]
WO WO2013113502A1
· 2013
[cited by applicant]
WO WO2013130161A1
· 2013
[cited by applicant]
WO WO2013151666A2
· 2013
[cited by applicant]
WO WO2013151663A1
· 2013
[cited by applicant]
WO WO2013151664A1
· 2013
[cited by applicant]
WO WO2013151665A2
· 2013
[cited by applicant]
WO WO2013151667A1
· 2013
[cited by applicant]
WO WO2013151668A2
· 2013
[cited by applicant]
WO WO2013151669A1
· 2013
[cited by applicant]
WO WO2013151670A2
· 2013
[cited by applicant]
WO WO2013151671A1
· 2013
[cited by applicant]
WO WO2013151672A2
· 2013
[cited by applicant]
WO WO2013151736A2
· 2013
[cited by applicant]
WO WO2013184976A2
· 2013
[cited by applicant]
WO WO2014028429A2
· 2014
[cited by applicant]
WO WO2014081507A1
· 2014
[cited by applicant]
WO WO2014093622A2
· 2014
[cited by applicant]
WO WO2014093574A1
· 2014
[cited by applicant]
WO WO2014093924A1
· 2014
[cited by applicant]
WO WO2014113089A2
· 2014
[cited by applicant]
WO WO2014152513A1
· 2014
[cited by applicant]
WO WO2014152659A1
· 2014
[cited by applicant]
WO WO2014152673A1
· 2014
[cited by applicant]
WO WO2014144039A1
· 2014
[cited by applicant]
WO WO2014144711A1
· 2014
[cited by applicant]
WO WO2014144767A1
· 2014
[cited by applicant]
WO WO2014152027A1
· 2014
[cited by applicant]
WO WO2014152030A1
· 2014
[cited by applicant]
WO WO2014152031A1
· 2014
[cited by applicant]
WO WO2014152211A1
· 2014
[cited by applicant]
WO WO2014152540A1
· 2014
[cited by applicant]
WO WO2014164253A1
· 2014
[cited by applicant]
WO WO2015006747A2
· 2015
[cited by applicant]
WO WO2015034925A1
· 2015
[cited by applicant]
WO WO2015034928A1
· 2015
[cited by applicant]
WO WO2015038892A1
· 2015
[cited by applicant]
WO WO2015051169A2
· 2015
[cited by applicant]
WO WO2015048744A2
· 2015
[cited by applicant]
WO WO2015051173A2
· 2015
[cited by applicant]
WO WO2015051214A1
· 2015
[cited by applicant]
WO WO2015058069A1
· 2015
[cited by applicant]
WO WO2015070413A1
· 2015
[cited by applicant]
WO WO2015085318A2
· 2015
[cited by applicant]
WO WO2015089511A2
· 2015
[cited by applicant]
WO WO2015101414A2
· 2015
[cited by applicant]
WO WO2015101416A1
· 2015
[cited by applicant]
WO WO2015105926A1
· 2015
[cited by applicant]
WO WO2015196118A1
· 2015
[cited by applicant]
WO WO2015196128A2
· 2015
[cited by applicant]
WO WO2015196130A2
· 2015
[cited by applicant]
WO WO2016010840A1
· 2016
[cited by applicant]
WO WO2016011222A2
· 2016
[cited by applicant]
WO WO2016011226A1
· 2016
[cited by applicant]
WO WO2016034620A1
· 2016
[cited by applicant]
WO WO2016036902A1
· 2016
[cited by applicant]
WO WO2016118724A1
· 2016
[cited by applicant]
WO WO2016118725A1
· 2016
[cited by applicant]
U.S. Appl. No. 61/404,413, Afeyan et al.
[cited by applicant]
U.S. Appl. No. 61/470,451, Afeyan et al.
[cited by applicant]
“AutoImmune shares collapse on Colloral data in rheumatoid arthritis,” Pharma MarketLetter,
[cited by applicant]
“Structure and Properties of Nucleosides and Nucleotides,” Department of Chemistry Lecture, University of Maine, <http://chemistry.umeche.maine.edu/CHY431/Basics/Nucleo.html>, retrieved on Dec. 12, 2014, last modified D…
[cited by applicant]
Agris et al., “Thermodynamic contribution of nucleoside modifications to yeast tRNA
[cited by applicant]
Akinc et al., Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms,Mol Ther. 2009 17:872-879.
[cited by applicant]
Alexopoulou et al., “Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3,” Nature 413:732-38 (2001).
[cited by applicant]
Anderson et al., “Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation,” Nucleic Acids Res. 38(17):5884-92 (2010).
[cited by applicant]
Anderson et al., “Nucleoside modifications in RNA limit activation of 2′-5′-oligoadenylate synthetase and increase resistance to cleavage by RNase L,” Nucleic Acids Res. 39(21): 9329-38 (Aug. 2011) (10 pages).
[cited by applicant]
Anderson, Bart R., Dissertation: “Nucleoside Modifications Suppress RNA Activation of Cytoplasmic RNA Sensors,” Doctor of Philosophy, Cell & Molecular Biology, University of Pennsylvania, 2010 (197 pages).
[cited by applicant]
Andries et al., “N1-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice,” J Control Rele…
[cited by applicant]
Applied Biosystems, DNA Synthesizer Model 380B Operations Manual, 2001 (327 pages).
[cited by applicant]
Aviv et al., “Purification of Biologically Active Globin Messenger RNA by Chromatography on Oligothymidylic acid-Cellulose,” Proc Nat Acad Sci USA 69(6):1408-1412 (1972).
[cited by applicant]
Bell et al., “In trans T cell tolerance diminishes autoantibody responses and exacerbates experimental allergic encephalomyelitis,” J Immunol. 180(3):1508-16 (2008).
[cited by applicant]
Berg et al., Chapter 4: DNA, RNA, and the Flow of Genetic Information.
[cited by applicant]
Berry & Associates, 2009 Product Catalog, downloaded Sep. 3, 2024 (288 pages).
[cited by applicant]
Bio-Rad Laboratories, Inc. “Stocking Up? Reagents and Supplies Quick Reference Guide,” <www.discover.bio-rad.com> (24 Pages).
[cited by applicant]
Brand et al., “Biosynthesis of a Hypermodified Nucleotide in
[cited by applicant]
Bélanger et al., “Characterization of hMTr1, a human Cap1 2′-O-ribose methyltransferase,” J Biol Chem. 285(43):33037-44 (2010).
[cited by applicant]
Chang et al., “Synthesis and solution conformation studies of 3-substituted uridine and pseudouridine derivatives,” Bioorg Med Chem. 16(5):2676-86 (2008) (11 pages).
[cited by applicant]
Charette et al., “Pseudouridine in RNA: What, Where, How, and Why,” IUBMB Life 49(5);341-51 (2000).
[cited by applicant]
Chatterjee et al., “The archaeal COG1901/DUF358 SPOUT-methyltransferase members, together with pseudouridine synthase Pus10, catalyze the formation of 1-methylpseudouridine at position 54 of tRNA,” RNA., 18(3):421-33 (M…
[cited by applicant]
Communication pursuant to Rule 164(2)(b) and Article 94(3) EPC for European Application No. 12722942.5, dated Mar. 9, 2018 (11 pages).
[cited by applicant]
Conrad et al., “Enzymatic synthesis of 2′-modified nucleic acids: identification of important phosphate and ribose moieties in RNase P substrates,” Nucleic Acids Res 23(11):1845-53 (1995).
[cited by applicant]
Davis et al., “Ribonucleic acids from yeast which contain a fifth nucleotide,” J Biol Chem., 227(2):907-15 (Aug. 1957).
[cited by applicant]
de Wet et al., “Firefly Luciferase Gene: Structure and Expression in Mammalian Cells,” Mol Cell Bio 7(2):725-37 (1987).
[cited by applicant]
Decision of Rejection for Japanese Patent Application No. 2016-148493, mailed Oct. 16, 2018 (6 pages).
[cited by applicant]
Derrigo et al., “RNA-protein interactions in the control of stability and localization of messenger RNA (review),” Int J Mol Med. 5(2):111-23 (2000).
[cited by applicant]
Diebold et al., “Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA,” Science. 303(5663): 1529-31 (2004).
[cited by applicant]
El-Sagheer et al., “Click nucleic acid ligation: applications in biology and nanotechnology,” Acc Chem Res. 45(8):1258-67 (2012).
[cited by applicant]
Examination Report for Canadian Application No. 2,831,613, dated Sep. 20, 2019 (4 pages).
[cited by applicant]
Fath et al., “Multiparameter RNA and codon optimization: a standardized tool to assess and enhance autologous mammalian gene expression,” PLoS One. 6(3):e17596 (2011) (14 pages).
[cited by applicant]
Feng et al., “MDA5 Detects the Double-Stranded RNA Replicative Form in Picornavirus-Infected Cells,” Cell Rep 2(5);1187-96 (Nov. 2012).
[cited by applicant]
Gallie et al., “Heat Shock Disrupts Cap and Poly(A) Tail Function during Translation and Increases mRNA Stability of Introduced Reporter mRNA,” Plant Physiol 108(4):1703-13 (1995).
[cited by applicant]
Gallie et al., “Post-transcriptional regulation in higher eukaryotes: The role of the reporter gene in controlling expression,” Mol Gen Genet 228:258-64 (1991).
[cited by applicant]
Gilham, “The Synthesis of Polynucleotide-Celluloses and Their Use in the Fractionation of Polynucleotides,” J Am Chem Soc. 86(22):4982-4985 (1964).
[cited by applicant]
Goodnow, “Pathways for self-tolerance and the treatment of autoimmune diseases,” Lancet. 357(9274):2115-21 (2001).
[cited by applicant]
Grosjean, Modification and editing of RNA: historical overview and important facts to remember.
[cited by applicant]
Hames et al., Processing of Eukaryotic Pre-mRNA.
[cited by applicant]
Hansen et al., “Circular RNA and miR-7 in Cancer,” Cancer Res. 73(18):5609-12 (Sep. 2013).
[cited by applicant]
Hansen et al., “Natural RNA circles function as efficient microRNA sponges,” Nature. 495(7441):384-8 (Feb. 2013) (7 pages).
[cited by applicant]
Haseltine et al., “Rous sarcoma virus genome is terminally redundant: the 5′ sequence,” Proc Natl Acad Sci USA. 74(3):989-93 (1977).
[cited by applicant]
Heil et al., “Species-Specific Recognition of Single-Stranded RNA via Toll-like Receptor 7 and 8.”
[cited by applicant]
Helm, M., “Post-transcriptional nucleotide modification and alternative folding of RNA,” Nucleic Acids Res 34(2):721-33 (2006).
[cited by applicant]
Henke et al., “microRNA-122 stimulates translation of hepatitis C virus RNA,” Embo J. 27(24):3300-10 (2008).
[cited by applicant]
Hikishima et al., “Synthesis of 1,8-naphthyridine C-nucleosides and their base-pairing properties in oligodeoxynucleotides: thermally stable naphthyridine:imidazopyridopyrimidine base-pairing motifs,” Angew Chem Int Ed.…
[cited by applicant]
Irier et al., “Translational regulation of GluR2 mRNAs in rat hippocampus by alternative 3′ untranslated regions,” available in PMC Aug. 17, 2009, published in final edited form as: J Neurochem. 109(2):584-594 (2009) (1…
[cited by applicant]
Ishii et al.,
[cited by applicant]
Ivanov et al., “RNA Synthesis by T7 RNA Polymerase Supported Primer Extension,” J Mol Biol 38(5):674-9 (2004).
[cited by applicant]
Jani et al., “In vitro transcription and capping of Gaussia luciferase mRNA followed by HeLa cell transfection,” J Vis Exp. 61:e3702 (2012) (9 pages).
[cited by applicant]
Jawalekar et al., “Oligonucleotide tagging for copper-free click conjugation,” Molecules. 18(7):7346-63 (Jul. 2013).
[cited by applicant]
Karikó et al., “Phosphate-enhanced transfection of cationic lipid-complexed mRNA and plasmid DNA,” Biochim Biophys Acta. 1369(2):320-34 (1998).
[cited by applicant]
Karikó et al., “Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA,” Nucleic Acids Res. 39(21):e142, DOI: 10.10…
[cited by applicant]
Karikó et al., “In vivo protein expression from mRNA delivered into adult rat brain,” J Neurosci Methods. 105(1): 77-86 (2001).
[cited by applicant]
Karikó et al., “Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability.” Mol Ther. 16(11):1833-40 (2008).
[cited by applicant]
Karikó et al., “Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin,” Mol Ther. 20(5): 948-953 (May 2012).
[cited by applicant]
Karikó et al., “mRNA is an endogenous ligand for Toll-like receptor 3,” J Biol Chem. 279(13):12542-50 (2004).
[cited by applicant]
Karikó et al., “Naturally occurring nucleoside modifications suppress the immunostimulatory activity of RNA: Implication for therapeutic RNA development,” Curr Opin Drug Discov Devel. 10(5): 523-532 (2007).
[cited by applicant]
Karikó et al., “Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA,” Immunity. 23(2):165-75 (2005).
[cited by applicant]
Karikó et al., Supplementary material for “Incorporation of Pseudouridine in mRNA Yields Superior Nonimmunogenic Vector with Increased Translational Capacity and Biological Stability,” Mol Ther 16(11):1833-40 (2008) (4 …
[cited by applicant]
Kierzek et al., “Influence of N6-isopentenyladenosine (i
[cited by applicant]
Kluiver et al., “Rapid generation of MicroRNA Sponges for MicroRNA Inhibition ,” PLoS One. 7(1):E29275 (Jan. 2012)(8 pages).
[cited by applicant]
Kore et al., “Synthesis and application of 2′-fluoro-substituted cap analogs,” Bioorg Med Chem Letters. 17:5295-9 (2007).
[cited by applicant]
Kormann et al., “Expression of therapeutic proteins after delivery of chemically modified mRNA in mice,” Nat Biotechnol. 29(2):154-7 (including supplement) (2011) (6 pages).
[cited by applicant]
Kozak, M., “Regulation of translation via mRNA structure in prokaryotes and eukaryotes,” Gene 361:13-37 (2005).
[cited by applicant]
Kraus et al., “Oral tolerance and inflammatory bowel disease,” Curr Opin Gastroenterol. 21(6):692-6 (2005).
[cited by applicant]
Kuribayashi-Ohta et al., “Application of oligo(dT)30-latex for rapid purification of poly(A)+ mRNA and for hybrid subtraction with the in situ reverse transcribed cDNA,” Biochim Biophys Acta. 1156(2):204-12 (1993).
[cited by applicant]
Kuwahara et al., “Molecular evolution of functional nucleic acids with chemical modifications,” Molecules. 15(8):5423-44 (2010).
[cited by applicant]
Li et al., “Effects of chemically modified messenger RNA on protein expression,” Bioconjug Chem. 27(3):849-53 (2016).
[cited by applicant]